Mood stabilizers and novel antipsychotics in the treatment of borderline personality disorder

Psychiatric Times

Volumn 23, Issue 8, 2006, Pages 25-33

  Bellino, Silvio ^a   Paradiso, Erika ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845775803     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
2. Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapy for Borderline John Wiley & Sons; 1999.
3. Livesley WJ. A practical approach to the treatment of patients with borderline personality disorder. Psychiatr Clin North Am. 2000;23:211 -232.
4. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Borderline Personality Disorder. Washington, DC: American Psychiatric Association; 2001.
5. Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol. 2005;20:225-236.
6. Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol, 1996;16:32S-47S.
7. Keck PE Jr, McElroy SL, Rieht N, Tonen M. What makes a drug a primary mood stabilizer? Mol Psy chiatry. 2002;7(suppl 1):S8-S14.
8. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002; 63:146-151.
9. Grof P. "Mood-stabilizers: the archeology of the concept" by M Harris, S Chandran, N Chakraborty and D Healy: a commentary. Bipolar Disord. 2003; 5:453-455.
10. Harris M, Chandran S, Chakraborty N, Healy D. Mood stabilizers: the archeology of the concept. Bipolar Disord. 2003;5:446-452.
11. Keck PE Jr, McElroy SL Redefining mood stabilization. J Affect Disord. 2003;73:163-169.
12. Mackinnon DF, Pies R. Affective instability as rapid cycling: theoretical and clinical implications for borderline personality and bipolar spectrum disorders. Bipolar Disord. 2006;8:1-14.
13. Zanarini MC, Frankenburg FR, Gunderson JG. Pharmacotherapy of borderline outpatients. Compr Psychiatry. 1988;29:372-378.
14. Gardner DL, Cowdry RW. Pharmacotherapy of borderline personality disorder: a review. Psychopharmacol Bull. 1989;25:515-523.
15. Goldberg SC. Prediction of change in borderline personality disorder. Psychopharmacol Bull. 1989; 25:550-555.
16. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4:117-128.
17. Links PS, Steiner M, Boiago I, et al. Lithium therapy for borderline patients: preliminary findings. J Clin Psychopharmacol, 1990;4:173-181.
18. Stein DJ. Drug treatment of the personality disorders. Br J Psychiatry. 1992;161:167-184.
19. Ghaemi SN, Ko JY. Oxcarbazepine treatment of bipolar disorder: a review of the literature. Primary Psychiatry, 2002;9:55-59.
20. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. Am J Psychiatry. 1986;143:519-522.
21. Cowdry RW, Gardner DL Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcipromine. Arch Gen Psychiatry. 1988;45:111-119.
22. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci. 1998;52:13-19.
23. Mattes J. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry Clin Neurosci. 1990;2:159-164.
24. Kravitz HM, Fawcett J. Carbamazepine in the treatment of affective disorders. Med Sci Res.1987;15: 1-8.
25. Blumer D, Heibronn M, Himmelhoch J. Indications forcarbamazepine in mental illness: atypical psychiatric disorder or temporal lobe syndrome? Compr Psychiatry. 1988;29:108-122.
26. Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI. Efficacy of carbamazepine compared with other agents: a clinical practice survey. J Clin Psychiatry. 1994;55:70-76.
27. Emrich H. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol. 1990;5 (suppl 1):83-88.
28. Hellewell JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord. 2002;72(suppl 1):S23-34.
29. Hummel B, Walden J, Stampfer R, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord. 2002;4:412-417.
30. Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in the treatment of affective and schizoaffective disorders. Fortschr Neurol Psychiatr. 2003;71:255-264.
31. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry. 2003;64(suppl 8):9-14.
32. Ghaemi SN, Berv DA, Klugman J, et al. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry. 2003;64:943-945.
33. Perugi G, Toni C, Frare F, et al. An open case study in Italy of oxcarbazepine, an effective mood stabilizer, in patients with drug resistant/intolerant bipolar I disorders. Poster presented at the XVI Congress of European College of Neuropsychopharmacology; September 20-24, 2003; Prague.
34. Raja M, Azzoni A. Oxcarbazepine versus valproate in mood and schizoaffective disorders. Int J Neuropsychopharm. 2003;6:409-414.
35. Benedetti A, Lattanzi L, Pini S, et al. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord. 2004;79:273-277.
36. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004;6:57-75.
37. Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. J Clin Psychiatry. 2004;5:738-739.
38. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry, 2004; 65(suppl 10):28-35.
39. Gentry JR, Hill C, Malcolm R. New anticonvulsants: a review of applications for the management of substance abuse disorders. Ann Clin Psychiatry. 2002;14:233-245.
40. Leweke FM, Gerth CW, Koethe D, et al. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry. 2004;161:1130-1131.
41. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2005;66:1111-1115.
42. Pole P. Enhancement of GABAergic inhibition: a mechanism of action of benzodiazepines, phenobarbital, valproate and L-cycloserine in the cat spinal cord. Electroencephalogr Clin Neurophysiol. 1982; 36(suppl):188-198.
43. Wilcox JA. Divalproex sodium in the treatment of aggressive behaviour. Ann Clin Psychiatry. 1994;6:17-20.
44. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry. 1995;7:33-37.
45. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry. 1995;56:506-510.
46. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behaviorin patients with personality disorder. J Clin Psychiatry. 1998;59:676-680.
47. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199-203.
48. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621-624.
49. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442-446.
50. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology. 1998;38:119-130.
51. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord. 1998;51:333-343.
52. Green B. Lamotrigine in mood disorders. Curr Med Res Opin. 2003;19:272-277.
53. Preston GA, Marchant BK, Reimherr FW, et al. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord. 2004;79:297-303.
54. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol, 2005;19:287-291.
55. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania: the Depakote Mania Study Group. JAMA. 1994;271:918-924.
56. Jarema M, Sartorius N. Treatment of bipolar disorders with second generation antipsychotic medications. Neuro Endocrinol Lett. 2005;26(suppl 1):5-7.
57. Malhi GS, Berk M, Bourin M, et al. Atypical mood stabilizers: a typical role for atypical antipsychotics. Acta Psychiatr Scand Suppl. 2005;(426):29-38.
58. Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry. 2005;39:652-661.
59. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 2005;7(suppl 4):21-33.
60. Conus P, Berk M, McGorry PD. Pharmacological treatment in the early phase of bipolar disorders: what stage are we at? Aust N Z J Psychiatry. 2006; 40:199-207.
61. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993;34:402-405.
62. Chengappa KN, Baker RW, Sirri C. The successful use of clozapine in ameliorating severe self-mutilating in a patient with borderline personality disorder. J Personal Disord. 1995;9:76-82.
63. Chengappa KN, Ebeling T, Kang JS, et al. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999;60:477-484.
64. Benedetti F, Sforzini L, Colombo C, et al. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998;59:103-107.
65. Swinton M. Clozapine in severe borderline personality. J Forensic Psychiatry. 2001;12:580-591.
66. Kouzam HR, Donnelly NJ. Remission of self-mutilation in a patient with borderline personality during risperidooe therapy. J Nerv Ment Dis. 1997:185:348-349.
67. Szighethy EM, Schulz SC. Risperidone in comor-bid borderline personality disorder and dysthymia. J Clin Psychopharmacol. 1997;17:326-327.
68. Hirpse S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psych Clin Neurosci. 2001;55:161 -162.
69. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002;63:241-244.
70. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111-161.
71. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46:1429-1435.
72. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: adouble-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854.
73. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
74. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903-907.
75. Soler J, Pascual JC, Barrachina J, et al. Doubleblind, placebo-controlled study of dialectical behavior therapy plus olanzapine tor borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224.
76. Kufferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology. 1997;133:323-328.
77. Hellewell JSE, Cameron Hands D, McKellar J. Seroquel: an effective atypical antipsychotic with no greater EPS than placebo across the full dose range. Schizophr Res. 1998;29:154.
78. Brecher M, Rak IW, Melvin K, et al. The longterm effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract. 2000;4:287-291.
79. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transient high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553-559.
80. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry. 2003;4:42-44.
81. Adityanjee A, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry. 2002;63(suppl 13):32-38.
82. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005;66:1298-1303.
83. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. In press.
84. Green B. Lamotrigine in mood disorders. Curr Med Res Opin. 2003;19:272-277.
85. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621-624.